Research record
Nivolumab
Nivolumab is a PD-1 immune checkpoint inhibitor. It is not a MEK inhibitor, and prior nivolumab exposure matters when discussing later options.
What this is
Nivolumab is a PD-1 immune checkpoint inhibitor. It is not a MEK inhibitor, and prior nivolumab exposure matters when discussing later options.
Why it may come up
- adjuvant
- cannot be removed by surgery
- has spread
- combination-dependent
What not to assume
- Do not describe nivolumab as a MEK drug.
- Do not give immune-toxicity management instructions beyond asking the care team.
At a glance
Nivolumab
- Type
- Immunotherapy
- Mutation result
- any
- Where
- US, Korea, Japan, China, EU
- Evidence status
- Approved in listed place
- Last checked
- 2026-05-20
What we know
- NCI PDQ lists immune checkpoint inhibitors as a melanoma treatment category.
- KCIC describes nivolumab as a PD-1 checkpoint inhibitor in Korean patient-facing material.
What is unclear
- Country-specific reimbursement and sequencing rules still need a formal map.
- Whether nivolumab is being used alone or in combination must be clarified.
Questions to ask
- Is nivolumab being discussed alone or with another immunotherapy?
- Is this before surgery, after surgery, or for cannot be removed by surgery/has spread disease?
- How does prior PD-1 exposure change later options?
Related trial leads
NCT04375527
Binimetinib and nivolumab in BRAF V600 wild-type melanoma
Supports the broader research concept of MEK inhibitor plus PD-1 inhibitor in melanoma, but not tunlametinib specifically.
NCT04835805
Belvarafenib alone or with cobimetinib or cobimetinib plus nivolumab in NRAS-mutant advanced melanoma
A sourced NRAS melanoma trial lead after anti-PD-1/PD-L1 therapy that may explain a remembered MEK/RAF plus PD-1 trial concept.
Related cohort stories
Lived experience only
Experiences with nivolumab plus ipilimumab in melanoma
A cohort-style thread for families to describe questions, side effects discussed, and what changed during care.